These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31474796)

  • 21. Determinants of the effectiveness of bezafibrate combined with ursodeoxycholic acid in patients with primary biliary cholangitis.
    Matsumoto K; Hirohara J; Takeuchi A; Miura R; Asaoka Y; Nakano T; Tanaka A
    Hepatol Res; 2023 Oct; 53(10):989-997. PubMed ID: 37291072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.
    Lens S; Leoz M; Nazal L; Bruguera M; Parés A
    Liver Int; 2014 Feb; 34(2):197-203. PubMed ID: 23998489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up.
    Sorda JA; González Ballerga E; Barreyro FJ; Avagnina A; Carballo P; Paes de Lima A; Daruich J
    Aliment Pharmacol Ther; 2021 Nov; 54(9):1202-1212. PubMed ID: 34587309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales.
    Colapietro F; Gershwin ME; Lleo A
    J Transl Autoimmun; 2023; 6():100188. PubMed ID: 36684809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.
    Hosonuma K; Sato K; Yamazaki Y; Yanagisawa M; Hashizume H; Horiguchi N; Kakizaki S; Kusano M; Yamada M
    Am J Gastroenterol; 2015 Mar; 110(3):423-31. PubMed ID: 25732417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
    Hazzan R; Tur-Kaspa R
    J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
    Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis.
    Fang YQ; Lv DX; Jia W; Li J; Deng YQ; Wang Y; Yu M; Wang GQ
    Medicine (Baltimore); 2014 Oct; 93(20):e104. PubMed ID: 25365404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
    Dohmen K; Tanaka H; Haruno M
    Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
    Reig A; Sesé P; Parés A
    Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review.
    Suraweera D; Rahal H; Jimenez M; Viramontes M; Choi G; Saab S
    Liver Int; 2017 Dec; 37(12):1877-1886. PubMed ID: 28517369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.
    Tanaka A; Hirohara J; Nakanuma Y; Tsubouchi H; Takikawa H
    J Gastroenterol; 2015 Jun; 50(6):675-82. PubMed ID: 25239675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
    Soret PA; Lam L; Carrat F; Smets L; Berg T; Carbone M; Invernizzi P; Leroy V; Trivedi P; Cazzagon N; Weiler-Normann C; Alric L; Rosa-Hezode I; Heurgué A; Cervoni JP; Dumortier J; Potier P; Roux O; Silvain C; Bureau C; Anty R; Larrey D; Levy C; Pares A; Schramm C; Nevens F; Chazouillères O; Corpechot C
    Aliment Pharmacol Ther; 2021 May; 53(10):1138-1146. PubMed ID: 33764590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study).
    Kong X; Kong Y; Zhang F; Wang T; Yan J
    Medicine (Baltimore); 2016 Oct; 95(40):e4949. PubMed ID: 27749550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
    Honda A; Ikegami T; Nakamuta M; Miyazaki T; Iwamoto J; Hirayama T; Saito Y; Takikawa H; Imawari M; Matsuzaki Y
    Hepatology; 2013 May; 57(5):1931-41. PubMed ID: 22911624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group.
    Poupon RE; Eschwège E; Poupon R
    J Hepatol; 1990 Jul; 11(1):16-21. PubMed ID: 1975819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis.
    Floreani A
    J Exp Pharmacol; 2020; 12():643-652. PubMed ID: 33364858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
    Corpechot C; Chazouillères O; Rousseau A; Le Gruyer A; Habersetzer F; Mathurin P; Goria O; Potier P; Minello A; Silvain C; Abergel A; Debette-Gratien M; Larrey D; Roux O; Bronowicki JP; Boursier J; de Ledinghen V; Heurgue-Berlot A; Nguyen-Khac E; Zoulim F; Ollivier-Hourmand I; Zarski JP; Nkontchou G; Lemoinne S; Humbert L; Rainteau D; Lefèvre G; de Chaisemartin L; Chollet-Martin S; Gaouar F; Admane FH; Simon T; Poupon R
    N Engl J Med; 2018 Jun; 378(23):2171-2181. PubMed ID: 29874528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
    Qian JD; Yao TT; Wang Y; Wang GQ
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.